9th Meeting of the European Forum on Antiphospholipid Antibodies

Scientific Program

Thursday, 16.05.2013

16.00–16.30	Welcome address Prof. Jacek Musiał – Chairman of the IX meeting of European Forum on Antiphospholipid Antibodies Prof. Wojciech Nowak – Rector of the Jagiellonian University Prof. Ricard Cervera – Chairman of Steering Committee of European Forum on Antiphospholipid Antibodies
	Antiphospholipid Syndrome (APS) – an overview (Chairs: Jacek Musiał, Ricard Cervera, Philip G. de Groot)
16.30–16.55	Thrombosis in APS–studies in Polish population Jacek Musiał
16.55–17.15	APS in Europe: Lessons from the "Euro-Phospholipid Project" Ricard Cervera
17.15–17.45	APS pathophysiology: basic science and laboratory issues Philip G. de Groot
18.00–22.00	Tour and get-together party in the Wieliczka Salt Mine
Friday, 17.05.2013
8.00–9.00	Poster set-up
	Session I APS – laboratory standardization (Chairs: Philip G. de Groot, Pier Luigi Meroni)
9.00–9.10	The updating on the APS-Action Pier Luigi Meroni
9.10–9.20	The new initiatives on standardization Pier Luigi Meroni
9.20.–9.40	Standardization of APA testing, a bridge too far? Philip G. de Groot
9.40–10.00	WGHA/EASI/IUIS anti-ß2GPI reference material Silvia S. Pierangeli
10.00–10.15	Lupus anticoagulant measurement: to mix or not to mix Rolf T. Urbanus
10.15–10.30	Antiphospholipid antibody testing anno 2013: how to make the best of it? Katrien Devreese
10.30–10.45	Future of LA ß2 dependent test and ß2 domain 1 ELISA Hilde Kelchtermans
10.45–11.00	General discussion about future projects
11.00–11.30	Coffee break
	Session II Criteria for the classification of the APS (Chairs: Vittorio Pengo, Jakub Swadźba)
11.30–11.50	Classification criteria of thrombotic APS Vittorio Pengo
11.50–12.05	Diagnosis of obstetric APS Hannah Cohen
12.05–12.20	The role of anti-prothrombin antibodies in the diagnosis of APS Maria Laura Bertolaccini
12.20–12.35	Role of isotype in ELISA tests for the diagnosis of APS Anna Vikerfors
12.35–12.50	Antiphospholipid syndrome nephropathy–diagnostic and management problems Maria Majdan
12.50–13.10	Clinical and laboratory criteria – which are more important? Jakub Swadźba
13.10–13.30	General discussion about future projects
13.30	European Forum on Antiphospholipid Antibodies: Steering Committee Meeting
13.30–15.00	Lunch/Poster Session
	Session III Obstetric/pediatric APS (Chairs: Amelia Ruffatti, Tadej Avcin)
15.00–15.20	Efficacy of the treatments in antiphospholipid syndrome pregnancy at high risk Amelia Ruffatti
15.20–15.35	Pathological mechanisms of antiphospholipid antibodies in trophoblastic cell fusion Philippe de Moerloose
15.35–15.50	The role of serum complement in the obstetric complications of the antiphospholipid syndrome Sara De Carolis
15.50–16.05	Treatment of refractory obstetric antiphospholipid syndrome: From bench to bedside Jaume Alijotas-Reig
16.05–16.25	Pediatric aspects of antiphospholipid syndrome Tadej Avcin
16.25–16.45	General discussion about future projects
16.45–17.15	Coffee break
	Session IV APS as an atypical autoimmune disease (Chairs: Yehuda Shoenfeld, Anna Jędryka-Góral)
17.15–17.35	To D or not to D? Yehuda Shoenfeld
17.35–17.50	Pathogenicity of anti-PL antibodies Martin Herrmann
17.50–18.05	Increased level of TNF-α as a marker of prothrombotic state in APS Jacek Musiał
18.05–18.20	Heart involvement in APS and SLE Wojciech Płazak
18.20–18.35	The avidity of anti-ß2-glycoprotein I antibodies Sasa Cucnik
18.35–18.45	General discussion about future projects
18.50	The European and the American members of the APS–ACTION meeting
20.00	Dinner on a barge moored at the Vistula Boulevard
Saturday, 18.05.2013
	Session V APS as a serious thrombotic disease (Chairs: Ricard Cervera, Anetta Undas)
9.00–9.20	CAPS Registry: Introducing the new website Ricard Cervera
9.20–9.40	A novel thrombotic mechanism in APS and its thromboembolic manifestations Anetta Undas
9.40–9.55	Thrombin generation in the diagnosis of APS Denis Wahl
9.55–10.10	ß2GPI selectively inhibits the procoagulant functions of thrombin Vincenzo De Filippis
10.10–10.25	Anti Domain I antibodies beyond thrombosis Cecilia Nalli
10.25–10.40	Thrombosis and APS Wojciech Sydor
10.40–11.00	General discussion about future projects
11.00–11.30	Coffee break
	Session VI Treatment in APS (Chairs: Angela Tincani, Samuel Machin)
11.30–11.50	Primary prophylaxis: to treat or not to treat? Angela Tincani
11.50–12.10	Treatment in APS – overview Samuel Machin
12.10–12.25	Shall we prescribe aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies? Laurent Arnaud
12.25–12.40	Hormonal contraception and antiphospholipid antibodies in infertile women Zdenka Ulcova–Gallova
12.40–13.00	Antimalarial in the treatment of APS Andrea Doria
13.00–13.15	General discussion about future projects
13.15–13.30	Closing remarks – Ricard Cervera, Jacek Musiał, Jakub Swadźba